Why Eli Lilly Stock Climbed Today
Key Points
Sales of Mounjaro and Zepbound soared in the second quarter.
Management lifted its full-year revenue forecast.
- 10 stocks we like better than Eli Lilly ›
Shares of Eli Lilly (NYSE: LLY) rose on Wednesday after the medicine maker highlighted the booming sales of its popular obesity treatments.
Image source: Getty Images.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Global growth
Eli Lilly's second-quarter revenue surged 48% year over year to $23 billion. The gains were broad-based, with U.S. sales up 33% to $14.4 billion and international revenue up 80% to $8.6 billion.
The healthcare giant's obesity drugs remain powerful growth drivers. Sales of Mounjaro and Zepbound soared 91% and 44%, respectively, to $9.9 billion and $4.9 billion.
Yet Eli Lilly's sterling performance extended beyond its popular weight-loss medicines. Revenue for key products in immunology, oncology, and neuroscience increased a whopping 121%.
All told, Eli Lilly's adjusted net income jumped 32% to $7.5 billion, or $8.38 per share. That was well above Wall Street's estimates, which had called for per-share profits of $6.58.
Stocking the pipeline
Encouraging ongoing sales trends prompted Eli Lilly to boost its full-year revenue target range to between $85 billion and $87 billion, up from a prior forecast of $82 billion to $85 billion.
Eli Lilly is using its surging profits from Mounjaro and Zepbound to bolster its development pipeline. The pharmaceutical titan recently acquired immunotherapy specialist Orna Therapeutics, neurology-focused Centessa Pharmaceuticals, and mental health treatment developer AtaiBeckley.
Eli Lilly also has potentially even more effective obesity drugs advancing through clinical trials.
"With our next-generation weight-loss medicine retatrutide and its complete clinical data package in hand, new manufacturing capacity coming online, and exciting new assets entering our pipeline through business development, Lilly's future, after 150 years, has never been brighter," CEO David Ricks said.
Should you buy stock in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $396,758!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,300,820!*
Now, it’s worth noting Stock Advisor’s total average return is 939% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of August 5, 2026.
Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly. The Motley Fool has a disclosure policy.
Recommended Articles
